BioAge Labs, Inc. Common Stock (BIOA) is a publicly traded Healthcare sector company. As of October 22, 2026, BIOA trades at $5.66 with a market cap of $252.89M and a P/E ratio of -2.97. BIOA moved +0.27% today. Year to date, BIOA is -56.18%; over the trailing twelve months it is -8.60%. Its 52-week range spans $2.88 to $25.96. Analyst consensus is buy with an average price target of $32.56. Rallies surfaces BIOA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for BIOA, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $5.66 |
| Market Cap | $252.89M |
| P/E Ratio | -2.97 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $25.96 |
| 52-Week Low | $2.88 |
| Volume | 408.20K |
| Avg Volume | 0 |
| Revenue (TTM) | $10.36M |
| Net Income | $-94.46M |
| Gross Margin | 0.00% |
10 analysts cover BIOA: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $32.56.